Molecular, histological, and clinical effects of selective TYK2 inhibition with zasocitinib (TAK-279) in patients with moderate-to-severe plaque psoriasis
Open Access
- 11 December 2025
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (5) , 1399-1403.e11
Abstract
No abstract availableKeywords
Funding Information
- Warner Bros. Discovery
- Takeda Pharmaceuticals International
This publication has 10 references indexed in Scilit:
- Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in PsoriasisJAMA Dermatology, 2024
- Clinical application of serum biomarkers for detecting and monitoring of chronic plaque psoriasisFrontiers in Molecular Biosciences, 2023
- TYK2 in Immune Responses and Treatment of PsoriasisJournal of Inflammation Research, 2022
- Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasisJournal of Allergy and Clinical Immunology, 2022
- IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasisJournal of Allergy and Clinical Immunology, 2019
- Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumabJournal of Allergy and Clinical Immunology, 2019
- Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's diseaseClinical and Experimental Immunology, 2016
- IL-19 Is a Component of the Pathogenetic IL-23/IL-17 Cascade in PsoriasisJournal of Investigative Dermatology, 2014
- β-Defensin-2 Protein Is a Serum Biomarker for Disease Activity in Psoriasis and Reaches Biologically Relevant Concentrations in Lesional SkinPLOS ONE, 2009
- Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple TestingJournal of the Royal Statistical Society Series B: Statistical Methodology, 1995